TY - JOUR T1 - Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report JF - The Journal of Rheumatology JO - J Rheumatol SP - 1536 LP - 1543 DO - 10.3899/jrheum.161145 VL - 44 IS - 10 AU - Susan J. Bartlett AU - Skye P. Barbic AU - Vivian P. Bykerk AU - Ernest H. Choy AU - Rieke Alten AU - Robin Christensen AU - Alfons den Broeder AU - Bruno Fautrel AU - Daniel E. Furst AU - Francis Guillemin AU - Sarah Hewlett AU - Amye L. Leong AU - Anne Lyddiatt AU - Lyn March AU - Pamela Montie AU - Christoph Pohl AU - Marieke Scholte Voshaar AU - Thasia G. Woodworth AU - Clifton O. Bingham III Y1 - 2017/10/01 UR - http://www.jrheum.org/content/44/10/1536.abstract N2 - Objective. The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop a reliable way to identify and measure RA flares in randomized controlled trials (RCT). Here, we summarized the development and field testing of the RA Flare Questionnaire (RA-FQ), and the voting results at OMERACT 2016.Methods. Classic and modern psychometric methods were used to assess reliability, validity, sensitivity, factor structure, scoring, and thresholds. Interviews with patients and clinicians also assessed content validity, utility, and meaningfulness of RA-FQ scores.Results. People with RA in observational trials in Canada (n = 896) and France (n = 138), and an RCT in the Netherlands (n = 178) completed 5 items (11-point numerical rating scale) representing RA Flare core domains. There was moderate to high evidence of reliability, content and construct validity, and responsiveness. Factor analysis supported unidimensionality. Rasch analysis showed acceptable fit to the Rasch model, with items and people covering a broad measurement continuum and evidence of appropriate targeting of items to people, ordered thresholds, minimal differential item functioning by language, sex, or age. A summative score across items is defensible, yielding an interval score (0–50) where higher scores reflect worsening flare. The RA-FQ received endorsement from 88% of attendees that it passed the OMERACT Filter 2.0 “Eyeball Test” for instrument selection.Conclusion. The RA-FQ has been developed to identify and measure RA flares. Its review through OMERACT Filter 2.0 shows evidence of reliability, content and construct validity, and responsiveness. These properties merit its further validation as an outcome for clinical trials. ER -